NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-29 13:10இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Krebs Biochemicals Reports Q2 FY27 Net Loss of ₹5.40 Cr; Revenue at ₹5.79 Cr
Krebs Biochemicals reported revenue from operations of ₹5.79 Cr (₹579.03 lacs) for Q2 ended September 30, 2026, up 38.9% YoY compared to ₹4.17 Cr in Q2 FY26, but down 17.1% QoQ. The company posted a net loss of ₹5.40 Cr (₹539.85 lacs) for the quarter, compared to a loss of ₹6.14 Cr in the year-ago period. Operations at the Vizag manufacturing plant remain closed following an Andhra Pradesh Pollution Control Board order dated February 7, 2025. Additionally, the Board previously approved an amalgamation with Ipca Laboratories Limited with an appointed date of April 1, 2026, which is pending necessary consents and approvals.
உச்சம் நம்பிக்கை
என்ன மாறியதுReported quarterly financial results for Q2 FY27 with continued net losses, negative net worth, and persistent closure of its Vizag unit.
ஏன் இது முக்கியம்The company continues to face severe operational and financial stress with deeply negative equity, making the pending merger with Ipca Laboratories critical for its survival and shareholder value.
Revenue from Operations (Q2): ₹579.03 lacsNet Loss (Q2): ₹539.85 lacsBasic EPS (Q2): ₹-2.50Non-current Borrowings: ₹15,450.00 lacsCurrent Borrowings: ₹7,248.56 lacs
📅 குறுகிய காலம்Trading sentiment is likely to remain muted given persistent net losses and the shuttered Vizag plant.
📈 நீண்ட காலம்Long-term prospects hinge almost entirely on the successful completion of the amalgamation into Ipca Laboratories, given Krebs' negative net worth and operational hurdles.
⚠ அபாய எச்சரிக்கைகள்
Negative net worth and high leverage with over ₹226 Cr in total borrowings
Vizag manufacturing facility remains shut by pollution control authorities since February 2025
Ongoing operational losses and dependence on promoter/parent support
👀 கவனிக்க வேண்டியவை
Track the regulatory approval process and timeline for the proposed amalgamation with Ipca Laboratories, along with updates on the revocation of the APPCB closure order for the Vizag facility.
Q1 FY27 Net Loss Narrows to ₹2.48 Cr; Revenue Up 27.4% YoY to ₹6.98 Cr
Krebs Biochemicals reported a 27.4% YoY increase in revenue from operations to ₹6.98 Cr (₹698.35 lacs) for Q1 ended June 30, 2026, compared to ₹5.48 Cr in Q1 FY26. Net loss narrowed significantly to ₹2.48 Cr from ₹5.32 Cr in the corresponding prior-year quarter. The company continues to face operational headwinds as its Vizag unit remains closed under an Andhra Pradesh Pollution Control Board order dated February 7, 2025. Additionally, the Board had previously approved the amalgamation of the company into Ipca Laboratories Limited (appointed date April 1, 2026), which remains subject to regulatory approvals.
உச்சம் நம்பிக்கை
என்ன மாறியதுQ1 FY27 operational results showed higher revenue and reduced net losses YoY, while plant closure and amalgamation proceedings continue.
ஏன் இது முக்கியம்The company has a deeply negative net worth (-₹162 Cr) and persistent net losses; progress on the proposed amalgamation with parent promoter Ipca Laboratories is the primary driver of future equity value.
📅 குறுகிய காலம்Financial performance continues to reflect constrained operations with negative net profit, though cost controls helped narrow losses YoY.
📈 நீண்ட காலம்Long-term outlook is fundamentally tied to the pending merger with Ipca Laboratories and resolution of environmental compliance at the Vizag unit.
⚠ அபாய எச்சரிக்கைகள்
Ongoing closure of the Vizag manufacturing unit by APPCB
Negative net worth and persistent net losses
Regulatory approval risks for the proposed amalgamation with Ipca Laboratories
👀 கவனிக்க வேண்டியவை
Track progress on the revocation of the APPCB closure order for the Vizag facility and monitor the statutory and shareholder approval milestones for the amalgamation with Ipca Laboratories.
KREBSBIO Board approves Q1 FY27 results; company faces Rs 225 Cr debt and negative net worth
Krebs Biochemicals and Industries Limited has approved its unaudited financial results for the quarter ended June 30, 2026. The company remains in a precarious financial position with a negative net worth of Rs 162 Cr and total debt of Rs 225 Cr. Historically, the company has struggled with profitability, reporting a net margin of -62.1% in FY25 and a net loss of Rs 26.92 Cr. Investors should monitor the full results for any signs of a turnaround through new product additions and promoter financial support.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has completed its board review and approved the financial performance data for the first quarter of the 2026-27 fiscal year.
ஏன் இது முக்கியம்Given the company's negative net worth and high debt, quarterly results are critical indicators of whether the business can sustain operations or if further promoter infusion is required.
Quarter ended: ஜூன் 30, 2026கடன்: Rs 225 கோடிNet worth: Rs -162 Crபுரமோட்டர் பங்கு: 72.7%FY25 Net Margin: -62.1%
📅 குறுகிய காலம்The stock may remain volatile as investors digest the specific revenue and loss figures from the Q1 filing.
📈 நீண்ட காலம்The long-term outlook is limited by material uncertainty regarding the company's ability to continue as a going concern unless it achieves a structural turnaround.
⚠ அபாய எச்சரிக்கைகள்
Going concern uncertainty
Negative net worth
High debt-to-equity ratio
Historical net losses
👀 கவனிக்க வேண்டியவை
Review the full financial statement to check for any improvement in operating profit margins and whether the auditors have continued the 'Going Concern' qualification.
Krebs Biochemicals to Merge with Ipca Laboratories; Share Swap Ratio Set at 7:200
Krebs Biochemicals & Industries Limited has approved a Scheme of Amalgamation to merge with Ipca Laboratories Limited. Under the proposed scheme, Krebs shareholders will receive 7 equity shares of Ipca Laboratories (Re. 1 each) for every 200 equity shares of Krebs (Rs. 10 each). The merger aims to integrate Krebs' specialized fermentation-based API manufacturing capabilities into Ipca's larger operations to secure supply chains and optimize costs. The appointed date for the merger is April 1, 2026, subject to regulatory and shareholder approvals.
முக்கிய அம்சங்கள்
Share swap ratio fixed at 7 shares of Ipca Laboratories for every 200 shares held in Krebs Biochemicals.Ipca Laboratories reported a standalone total income of ₹7,431 Crores for FY26, while Krebs reported ₹26 Crores.The merger will provide Ipca with unique fermentation-based API manufacturing facilities that it currently lacks.Krebs is currently loss-making and will benefit from Ipca's financial strength and R&D capabilities.The appointed date for the scheme is April 1, 2026, and it remains subject to SEBI and NCLT approvals.
👀 கவனிக்க வேண்டியவை
Investors should evaluate the merger based on the current market price of Ipca Laboratories to determine if the 7:200 swap ratio offers a premium over Krebs' current stock price. The merger provides Krebs shareholders an exit into a much larger, diversified, and profitable pharmaceutical entity.
Krebs Biochemicals FY26 Revenue Drops 45% to ₹23.7 Cr; Net Loss Narrows to ₹16.9 Cr
Krebs Biochemicals reported a sharp 45.2% decline in annual revenue to ₹23.73 crore for FY26, largely due to the continued closure of its Vizag manufacturing unit since February 2025. While the annual net loss narrowed to ₹16.93 crore from ₹26.94 crore in FY25, the company's financial health remains critical with a deeply negative net worth of ₹162.75 crore. Operations at the Vizag plant remain suspended following orders from the Andhra Pradesh Pollution Control Board, significantly impacting production capacity.
முக்கிய அம்சங்கள்
Annual revenue from operations fell 45.2% YoY to ₹2,373.16 lacs from ₹4,331.19 lacs.Net loss for the full year narrowed to ₹1,693.31 lacs compared to a loss of ₹2,693.93 lacs in the previous year.The Vizag manufacturing unit remains closed since Feb 7, 2025, due to a Pollution Control Board order.Net worth deteriorated further to negative ₹16,275.47 lacs as of March 31, 2026.Finance costs rose to ₹708.59 lacs for FY26, up from ₹591.42 lacs in FY25, indicating increasing debt servicing pressure.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution due to the company's negative net worth and the ongoing regulatory suspension of its primary manufacturing facility. Avoid fresh positions until there is a clear roadmap for plant reopening and capital restructuring.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Krebs Biochemicals Q3 Loss Narrows to ₹3.13 Cr; Revenue Declines 36% YoY
Krebs Biochemicals reported a sharp 36.6% YoY decline in revenue from operations to ₹7.27 crore for the quarter ended December 31, 2025. Despite the revenue drop, the company narrowed its net loss to ₹3.13 crore from ₹7.74 crore in the previous year's corresponding quarter, largely due to a significant reduction in operating expenses. A major operational headwind persists as the Vizag manufacturing unit remains closed following a February 2025 order from the Andhra Pradesh Pollution Control Board. The company's financial position is critical, with a negative net worth of ₹160.83 crore and total borrowings exceeding ₹221 crore.
முக்கிய அம்சங்கள்
Revenue from operations fell to ₹727.42 lacs in Q3 FY26 compared to ₹1,146.72 lacs in Q3 FY25.Net loss for the quarter narrowed to ₹312.65 lacs from ₹773.89 lacs YoY.Total expenses were reduced by approximately 46% YoY to ₹1,040.49 lacs.The Vizag manufacturing unit remains shut down since February 7, 2025, due to regulatory orders.Company reports a deeply negative net worth of ₹16,083.25 lacs as of December 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should remain highly cautious as the company faces severe financial distress with negative net worth and ongoing regulatory issues at its Vizag plant. The significant drop in revenue and high debt levels make this a high-risk situation despite the narrowing of quarterly losses.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
